Oncolytics Biotech (ONC) Competitors C$1.60 +0.09 (+5.96%) As of 07/11/2025 03:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesBuy This Stock ONC vs. PLI, ABCN, EMC, FRX, BCT, IPA, TH, SCYB, COM, and NVHShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). These companies are all part of the "biotechnology" industry. Oncolytics Biotech vs. Its Competitors ProMetic Life Sciences VIVO Cannabis Emblem Fennec Pharmaceuticals BriaCell Therapeutics ImmunoPrecise Antibodies Theratechnologies Scythian Biosciences 138267 (COM.TO) Novoheart Oncolytics Biotech (TSE:ONC) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation. Which has better earnings and valuation, ONC or PLI? Oncolytics Biotech has higher earnings, but lower revenue than ProMetic Life Sciences. Oncolytics Biotech is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-C$27.66M-C$0.36-4.46ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A Does the media prefer ONC or PLI? In the previous week, Oncolytics Biotech had 23 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 23 mentions for Oncolytics Biotech and 0 mentions for ProMetic Life Sciences. Oncolytics Biotech's average media sentiment score of 0.30 beat ProMetic Life Sciences' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the media. Company Overall Sentiment Oncolytics Biotech Neutral ProMetic Life Sciences Neutral Is ONC or PLI more profitable? ProMetic Life Sciences' return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -141.94% -71.33% ProMetic Life Sciences N/A N/A N/A Do analysts prefer ONC or PLI? Oncolytics Biotech presently has a consensus price target of C$3.50, indicating a potential upside of 118.75%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than ProMetic Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ProMetic Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in ONC or PLI? 1.8% of Oncolytics Biotech shares are held by institutional investors. 3.8% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryOncolytics Biotech beats ProMetic Life Sciences on 8 of the 12 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricOncolytics BiotechBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$123.32MC$129.27MC$5.56BC$6.20BDividend Yield0.31%3.74%5.06%6.72%P/E Ratio-4.463.4728.2650.47Price / SalesN/A4,141.03436.611,211.67Price / Cash4.2213.1937.1283.29Price / Book13.6142.088.044.70Net Income-C$27.66M-C$92.15MC$3.19BC$301.20M7 Day Performance39.13%1.37%3.62%1.05%1 Month Performance95.12%5.67%5.98%4.15%1 Year Performance11.11%169.31%29.39%25.91% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOncolytics Biotech1.0638 of 5 starsC$1.60+6.0%C$3.50+118.8%+11.1%C$123.32MN/A-4.4629Analyst RevisionPLIProMetic Life SciencesN/AN/AN/AN/AC$317.06MC$39.91M-0.22487ABCNVIVO CannabisN/AC$1.32+5.6%N/A+0.0%C$256.62MN/A0.00N/AGap UpEMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/AFRXFennec PharmaceuticalsN/AC$11.89+2.3%N/A+38.9%C$229.30MC$34.86M-201.4110News CoverageGap UpBCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195News CoverageIPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080News CoverageGap DownTHTheratechnologiesN/AC$4.30-0.7%N/A+118.3%C$137.19MC$52.22M-48.67103SCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/A Related Companies and Tools Related Companies ProMetic Life Sciences Alternatives VIVO Cannabis Alternatives Emblem Alternatives Fennec Pharmaceuticals Alternatives BriaCell Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Theratechnologies Alternatives Scythian Biosciences Alternatives 138267 (COM.TO) Alternatives Novoheart Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:ONC) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONC Stock Alerts